Zinplava bezlotoxumab regulatory update

FDA’s Antimicrobial Drugs Advisory Committee voted 10-5, with 1 abstention, that Merck provided substantial evidence that Zinplava bezlotoxumab is

Read the full 193 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE